StreetInsider.com News Articles

Form SCHEDULE 13G CytomX Therapeutics, Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260727/26819960.html

Form SCHEDULE 13G CytomX Therapeutics, Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260727/26819960.html

Form 8-K CytomX Therapeutics, For: Jul 24

Mon, 27 Jul 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260727/26816446.html

Form 8-K CytomX Therapeutics, For: Jul 24

Mon, 27 Jul 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260727/26816446.html

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Fuchs most recently served as chief medical officer of Tubulis, where he oversaw clinical strategy and pipeline development. Before that, he was senior vice president and global head of oncology and hematology drug development at Genentech and Roche, where he led multiple therapies to regulatory approval, including Lunsumio, Columvi, Polivy, and Tecentriq.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics adds oncologist Charles Fuchs to its board

Mon, 27 Jul 2026 08:00:33 -0400

CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors